News

• Swift Biosciences Introduces Accel-NGS™ DNA Library Kit

  Press Release - Ann Arbor, MI - 27-Feb-2013

  Swift Biosciences, Inc. today announced the launch of the Accel-NGS™ DNA Library Kit, the first product in a new line of kits for Next Generation Sequencing (NGS) sample preparation. NGS users can now produce PCR-free libraries with as little as 5 ng of input DNA.
  

  
  

  Read the full article

  Swift Biosciences Introduces Accel-NGS™ DNA Library Kit

  Press Release - Ann Arbor, MI - 27-Feb-2013

• Michigan Accelerator Fund I Invests $750,000 in Swift Biosciences

  Press Release - Grand Rapids, MI - 15-Jan-2013

  Michigan Accelerator Fund I (MAF‐1) has made a $750,000 Series A‐1 investment in Swift Biosciences, Inc. This is the seventh company MAF‐1 has funded since the fund’s inception in 2010, and the first investment since the fund closed at $15.1M in August of 2012.

  
  

  Read the full article

  Michigan Accelerator Fund I Invests $750,000 in Swift Biosciences

  Press Release - Grand Rapids, MI - 15-Jan-2013

• Swift Biosciences Signs Technology License Agreement with VelaDx

  Press Release - Ann Arbor, MI - 03-Dec-2012

  Swift Biosciences, Inc. today announced that it has signed a technology license agreement with Vela Operations Pte. Ltd, the Singapore-based parent of Vela Diagnostics. The agreement gives Vela non-exclusive rights to utilize Swift’s myT® Primer technology in Vela’s real-time quantitative PCR-based IVD products for the detection of somatic mutations in human cancer.

  
  

  Read the full article

  Swift Biosciences Signs Technology License Agreement with VelaDx

  Press Release - Ann Arbor, MI - 03-Dec-2012

• Swift Biosciences Covered in GenomeWeb's PCR Insider Product Watch

  GenomeWeb - 27-Sep-2012

  Swift Biosciences has announced a new addition to its line of myT Primer reagents to detect key cancer mutations.

  
  

  Read the full article

  Swift Biosciences Covered in GenomeWeb's PCR Insider Product Watch

  GenomeWeb - 27-Sep-2012

• Swift Biosciences Introduces myT® BRAF-Ultra

  Press Release - Ann Arbor, MI - 17-Sep-2012

  Swift Biosciences, Inc. has announced a new addition to its line of myT® Primer reagents for the detection of key cancer mutations. myT BRAF-Ultra, an ultrasensitive version of myT BRAF, provides 0.01% sensitivity down to single copy detection of BRAF mutations and is now available from Swift.

  
  

  Read the full article

  Swift Biosciences Introduces myT® BRAF-Ultra

  Press Release - Ann Arbor, MI - 17-Sep-2012

• Swift Biosciences Launches BRAF Mutation Assay; Tacks on $2.4M to Series A Financing Round

  GenomeWeb - 23-Feb-2012

  "Swift Biosciences this week announced the formal commercial launch of its first product, a BRAF mutation-detection assay based on the company's proprietary "myT Primer" qPCR reagents."

  Read the full article

  Swift Biosciences Launches BRAF Mutation Assay; Tacks on $2.4M to Series A Financing Round

  GenomeWeb - 23-Feb-2012

• Swift Biosciences Introduces myT™ BRAF

  Press Release - Ann Arbor, MI - 20-Feb-2012

  Swift Biosciences, Inc. today announced their new line of myT™ Primer reagents for the detection of key cancer mutations.

  Read the full article

  Swift Biosciences Introduces myT™ BRAF

  Press Release - Ann Arbor, MI - 20-Feb-2012

• Swift Biosciences Covered in Crain's Detroit Business

  Crain's Detroit Business - 12-Feb-2012

  "David Olson grew up as a nature lover, not exactly on a path to commercialize research used in the fight against cancer.

  Yet that's where this entrepreneur has landed, most recently as the founder of Ann Arbor-based Swift Biosciences Inc. The company develops molecular biology reagents for research and diagnostic applications, and its technologies offer new ways to examine disease-related genes and enable tools for managing cancer."

  Read the full article

  Swift Biosciences Covered in Crain's Detroit Business

  Crain's Detroit Business - 12-Feb-2012

• Swift Biosciences Adds Senior Executive for Commercialization

  Press Release - Ann Arbor, MI - 10-Mar-2011

  Swift Biosciences Inc. today announced that Steve Spotts has joined the company as Chief Commercial Officer.

  Read the full article

  Swift Biosciences Adds Senior Executive for Commercialization

  Press Release - Ann Arbor, MI - 10-Mar-2011

• Swift Biosciences Unveils qPCR Primer Tech; Hopes to Market First Product by Year's End

  GenomeWeb - 24-Feb-2011

  "Swift this week publicly presented the first research results for its core technology, a new kind of highly sensitive qPCR primer designed for mutation and low copy number detection, and said it would eventually market products in the research, diagnostics, and next-generation sequencing spaces."

  Read the full article

  Swift Biosciences Unveils qPCR Primer Tech; Hopes to Market First Product by Year's End

  GenomeWeb - 24-Feb-2011

• Swift Biosciences Announces Performance Data for Mutation Detection

  Press Release - San Francisco, CA - 23-Feb-2011

  Swift Biosciences Inc., a developer of innovative genetic analysis tools for the research and diagnostic markets, today presented at the 18th International Molecular Medicine Tri-Conference their high performance qPCR myT™ Primers for highly sensitive, highly specific detection of cancer mutations.

  Read the full article

  Swift Biosciences Announces Performance Data for Mutation Detection

  Press Release - San Francisco, CA - 23-Feb-2011

• Swift Biosciences Announces $3M Series A

  Press Release - Ann Arbor, MI - 10-Aug-2010

  Swift Biosciences Inc., a Michigan-based life sciences company, today announced the recent completion of a $3 million Series A financing led by the venture firm DFJ Mercury. DFJ Mercury was joined in the Series A by several Michigan-based individual investors who also helped launch the Company with seed funding in January 2010.

  Read the full article

  Swift Biosciences Announces $3M Series A

  Press Release - Ann Arbor, MI - 10-Aug-2010